Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The estrogen receptor-alpha (ERalpha) pituitary-specific variant,
TERP
-1, is regulated dramatically by physiological status. We examined hormonal regulation of the
TERP
-1 promoter in transient transfection assays in GH3 somatolactotrope cells. We found that 17beta-estradiol (E2), genistein, androgen, pituitary
adenylate cyclase
-activating peptide, and forskolin (FSK) all stimulated
TERP
-1 promoter activity, whereas progesterone had no effect. ERalpha bound to a palindromic estrogen response element (ERE) and two half-site EREs; mutation of any of these sites decreased basal expression and completely obliterated E2 stimulation. In contrast, mutation of an activator protein-1 site decreased basal and FSK-stimulated promoter activity, but not E2 or androgen stimulation. The pure antiestrogen ICI 182,780 suppressed E2 and genistein, but not FSK or androgen, stimulation. Similarly, mutation of the ERE palindrome or half-site EREs suppressed promoter stimulation by E2 and genistein, but not by androgen or FSK. Because
TERP
-1 levels regulate ERalpha function on model promoters, we tested
TERP
-1 modulation of its own and other physiological promoters.
TERP
-1 suppressed basal and E2-stimulated expression of its own promoter.
TERP
-1 suppression required the ERE regions of the promoter, and the dimerization domain of
TERP
-1.
TERP
-1 overexpression also suppressed E2 stimulation of the progesterone receptor and prolactin promoters. Thus, estrogens, androgen, and FSK can stimulate
TERP
-1 promoter activity, and increased
TERP
-1 expression modulates E2 stimulation of physiological promoters. These data suggest that
TERP
-1 regulation may play a significant role in modifying pituitary ERalpha responses.
...
PMID:Stimulation of the novel estrogen receptor-alpha intronic TERP-1 promoter by estrogens, androgen, pituitary adenylate cyclase-activating peptide, and forskolin, and autoregulation by TERP-1 protein. 1621 Mar 60